Compare Citius Pharmaceuticals Inc (CTXR) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Palo Alto Networks Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Palo Alto Networks Inc trades at $418.78 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 24358.3× Citius Pharmaceuticals Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Palo Alto Networks Inc for 82 Days on average.
| CTXR | PANW | |
|---|---|---|
Market Cap | $13.62M | $331.76B |
Volume | 132,438 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $1.82 | $419.91 |
52-Week Low | $0.48 | $141.67 |
Typical Hold Time | 17 Days | 82 Days |
Enterprise Value | $3.79M | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
Palo Alto Networks (PANW) trades at $398.50, down 1.7% on the day but near its 52-week high, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth is robust, rising from $5.5B in 2022 to $9.2B in 2025, though net income margin compressed to 2.67% in 2026 from 12.29% in 2025. Positive sentiment is driven by AI cybersecurity demand and platformization strategy.
The outlook remains favorable given strong analyst support (72% buy ratings) and a consensus price target of $398.70, but high valuation multiples (P/E 1,013.93, P/S 26.99) and rising costs pose risks. Earnings execution and AI-driven security adoption are key catalysts, while premium valuation and competitive pressures require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
